163 related articles for article (PubMed ID: 18402255)
1. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma.
Tong QS; Zheng LD; Tang ST; Ruan QL; Liu Y; Li SW; Jiang GS; Cai JB
World J Pediatr; 2008 Feb; 4(1):58-62. PubMed ID: 18402255
[TBL] [Abstract][Full Text] [Related]
2. Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray.
Mehrazma M; Madjd Z; Kalantari E; Panahi M; Hendi A; Shariftabrizi A
Fetal Pediatr Pathol; 2013 Jun; 32(3):192-204. PubMed ID: 22830353
[TBL] [Abstract][Full Text] [Related]
3. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway.
Sartelet H; Imbriglio T; Nyalendo C; Haddad E; Annabi B; Duval M; Fetni R; Victor K; Alexendrov L; Sinnett D; Fabre M; Vassal G
Histopathology; 2012 Jun; 60(7):1144-55. PubMed ID: 22394107
[TBL] [Abstract][Full Text] [Related]
4. Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model.
Coulon A; Flahaut M; Mühlethaler-Mottet A; Meier R; Liberman J; Balmas-Bourloud K; Nardou K; Yan P; Tercier S; Joseph JM; Sommer L; Gross N
Neoplasia; 2011 Oct; 13(10):991-1004. PubMed ID: 22028624
[TBL] [Abstract][Full Text] [Related]
5. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.
Takenobu H; Shimozato O; Nakamura T; Ochiai H; Yamaguchi Y; Ohira M; Nakagawara A; Kamijo T
Oncogene; 2011 Jan; 30(1):97-105. PubMed ID: 20818439
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
10. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
Qu H; Li R; Liu Z; Zhang J; Luo R
Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
13. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis.
Mia-Jan K; Munkhdelger J; Lee MR; Ji SY; Kang TY; Choi E; Cho MY
Tohoku J Exp Med; 2013 Apr; 229(4):301-9. PubMed ID: 23615455
[TBL] [Abstract][Full Text] [Related]
15. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors.
Sabet MN; Rakhshan A; Erfani E; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000
[TBL] [Abstract][Full Text] [Related]
17. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
[TBL] [Abstract][Full Text] [Related]
18. Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma.
Kim K; Ro JY; Kim S; Cho YM
Hum Pathol; 2012 Dec; 43(12):2109-16. PubMed ID: 22944295
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer.
Elbasateeny SS; Salem AA; Abdelsalam WA; Salem RA
Pathol Res Pract; 2016 Jan; 212(1):10-6. PubMed ID: 26608413
[TBL] [Abstract][Full Text] [Related]
20. Research progression of CD133 as a marker of cancer stem cells.
Zhang H; Li SY
Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
